Patient Journey With Advanced Lung Cancer Positive for ALK Fusion in Brazil

计划入组 101 人 · 首次发布于 2021 年 7 月 1 日

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

计划入组 15 人 · 首次发布于 2024 年 3 月 27 日

The Study of Exosome EML4-ALK Fusion in NSCLC Clinical Diagnosis and Dynamic Monitoring

计划入组 75 人 · 首次发布于 2020 年 8 月 5 日

EML-4-ALK Fusion

GLP-1/A1AT fusion proteins

Cytokine fusion proteins(MIT)

FUSION PHARMACEUTICALS

Nepal

Biomea Fusion

United States

Fusion Pharmaceuticals Inc.

TRIANA Biomedicines' TRI-611 Receives FDA Fast Track Designation for ALK+ NSCLC Treatment

Chugai's Alecensa Receives World's First Tumor-Agnostic Approval for ALK Fusion-Positive Solid Tumors

FDA Clears HanchorBio's HCB101 Single-Patient Expanded Access Protocol, a First for SIRPα-Fc Fusion Proteins